Industry have responded favourably to the publication of the government’s Life Sciences Industrial Strategy today, which is aimed at helping the sector become an international benchmark for success.
Recently, there has been a shift within the pharmaceutical industry veering its R&D away from the traditional corporate campuses and moving them to new collaborative biotech clusters. Nick Sutcliffe, discusses the risks and opportunities of the trend
Indivior, a speciality pharmaceutical company, has opened a $30 million research and development (R&D) centre in Hull, UK, to further advance its treatment innovation into the global addiction crisis.
Here, we talk work, life and pharma with Alessandra Rispoli who has been appointed to serve as senior director, Operations for West Pharmaceutical Services’ manufacturing site in Eschweiler, Germany.
Contract development and manufacturing organisation (CDMO) that specialises in spray drying and capsule filling services, Micro-Sphere, is investing €19 million to expand its GMP manufacturing capabilities at its Swiss facility.
Incorporating telehealth solutions into new drug delivery technologies like nanomedicines can potentially give pharmaceuticals the edge they need to win the fight against disease, says Alexander Myskiw, healthcare & life sciences practice, DataArt
A new study from Best Practices has revealed that even though the uptake in tablet technology has increased in popularity for field-based medical roles, such as MSLs, this has not necessarily translated into improved effectiveness.
Event organisers, UBM EMEA, UBM Sinoexpo and China Chamber of Commerce for Import & Export of Medicines & Health Products (CCCMHPIE), have announced growth in both overall visits and overseas visits for the latest CPhI and P-MEC China event.
CPhI has released the findings of its 2017 India Pharma Market Report, identifying improved international repute of India but an urgent call for government support for investment in active pharmaceutical ingredient (API) facilities.
Global pharmaceutical and biopharmaceutical open access capability platform, WuXi AppTec, has published a report on immunotherapy, identifying that smaller biotech firms and early-stage companies will be the biggest driver behind therapy innovation.
